MoleculdOS, an AI-driven drug design platform from Chinese biotech firm MoleculdOS, has demonstrated its capabilities in designing novel cyclic peptides for protein-protein interaction targets like p53-MDM2 and PD-L1. This follows a recent success in designing nanobodies, showcasing the platform's versatility across different molecular modalities. The platform's ability to compress candidate spaces before wet lab experiments is expected to significantly reduce R&D costs and time in drug discovery, particularly for complex targets. AI
IMPACT Accelerates drug discovery for complex targets by reducing R&D time and costs through AI-driven molecular design.
RANK_REASON AI biotech company announces new capabilities and platform release for drug design. [lever_c_demoted from frontier_release: ic=1 ai=1.0]
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
